PSFG
GILD icon

Park Square Financial Group’s Gilead Sciences GILD Stock Holding History

Park Square Financial Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.06K Buy
+48
New +$6.32K 0.05% 114
2025
Q3 		– Sell
-95
Closed -$10.5K – 533
2025
Q2 		$10.5K Buy
+95
New +$10.1K 0.01% 585

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Park Square Financial Group's GILD Position: Q2 2026 in Review

Park Square Financial Group opened a new position in Gilead Sciences (GILD) in Q2 2026: 48 shares worth $6.06K. The stake represents 0.05% of the portfolio and ranks #114 among its holdings. This is a return to the name: Park Square Financial Group previously reported a position in GILD as recently as Q2 2025.

Park Square Financial Group first reported a position in GILD in Q2 2025 and has held it in 2 quarters since. The position peaked at $10.5K in Q2 2025. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Park Square Financial Group held 48 shares of Gilead Sciences worth $6.06K as of Q2 2026.
  • Gilead Sciences was a new Park Square Financial Group position in Q2 2026.
  • Gilead Sciences made up 0.05% of Park Square Financial Group's portfolio in Q2 2026, its #114 holding.
  • Park Square Financial Group first reported a position in Gilead Sciences in Q2 2025 and has held it in 2 quarters since.
  • Park Square Financial Group's Gilead Sciences position peaked at $10.5K in Q2 2025.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Park Square Financial Group's 13F filing for Q2 2026, filed 31 Jul 2026.